Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (53) 53
oncology (42) 42
male (39) 39
female (38) 38
middle aged (38) 38
aged (33) 33
index medicus (28) 28
adult (27) 27
treatment outcome (20) 20
lung neoplasms - drug therapy (19) 19
aged, 80 and over (18) 18
cancer (17) 17
neoplasm staging (15) 15
article (14) 14
kidney neoplasms - therapy (14) 14
carcinoma, non-small-cell lung - drug therapy (13) 13
carcinoma, renal cell - therapy (13) 13
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
immunotherapy (11) 11
lung neoplasms - pathology (11) 11
survival rate (11) 11
kidney neoplasms - pathology (10) 10
prognosis (10) 10
respiratory system (10) 10
chemotherapy (9) 9
antineoplastic agents - therapeutic use (8) 8
carcinoma, renal cell - pathology (8) 8
care and treatment (8) 8
kidney neoplasms - mortality (8) 8
lung cancer (8) 8
lung neoplasms - mortality (8) 8
solid tumors (8) 8
survival analysis (8) 8
therapy (8) 8
carcinoma, non-small-cell lung - mortality (7) 7
carcinoma, non-small-cell lung - pathology (7) 7
carcinoma, renal cell (7) 7
carcinoma, renal cell - immunology (7) 7
carcinoma, renal cell - mortality (7) 7
clinical trials (7) 7
kidney neoplasms - immunology (7) 7
nephrectomy (7) 7
retrospective studies (7) 7
survival (7) 7
urology & nephrology (7) 7
adenocarcinoma - drug therapy (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
dendritic cells - immunology (6) 6
disease-free survival (6) 6
docetaxel (6) 6
drug therapy (6) 6
follow-up studies (6) 6
interleukin-2 (6) 6
young adult (6) 6
carcinoma (5) 5
carcinoma, renal cell - secondary (5) 5
disease progression (5) 5
dose-response relationship, drug (5) 5
erlotinib (5) 5
expression (5) 5
hematology, oncology and palliative medicine (5) 5
immunology (5) 5
immunotherapy - methods (5) 5
interleukin-2 - therapeutic use (5) 5
lung cancer, non-small cell (5) 5
maximum tolerated dose (5) 5
medicine, research & experimental (5) 5
neoplasms - drug therapy (5) 5
neoplasms - pathology (5) 5
protein kinase inhibitors - therapeutic use (5) 5
pulmonary/respiratory (5) 5
renal cell carcinoma (5) 5
research (5) 5
trial (5) 5
adenocarcinoma (4) 4
animals (4) 4
antimitotic agents (4) 4
antineoplastic agents (4) 4
cancer research (4) 4
cancer vaccines - therapeutic use (4) 4
cell lung-cancer (4) 4
cisplatin (4) 4
classification (4) 4
combination (4) 4
combined modality therapy (4) 4
flt3 ligand (4) 4
gefitinib (4) 4
growth (4) 4
interleukin-4 - administration & dosage (4) 4
kidney (4) 4
medicine & public health (4) 4
necrosis-factor-alpha (4) 4
neoplasm metastasis (4) 4
neoplasm recurrence, local - drug therapy (4) 4
non-small cell lung cancer (4) 4
open-label (4) 4
paclitaxel (4) 4
phenotype (4) 4
pulmonary and respiratory medicine (4) 4
quinazolines - therapeutic use (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors
by Liu, Stephen V and Groshen, Susan G and Kelly, Karen and Reckamp, Karen L and Belani, Chandra and Synold, Timothy W and Goldkorn, Amir and Gitlitz, Barbara J and Cristea, Mihaela C and Gong, I-Yeh and Semrad, Thomas J and Xu, Yucheng and Xu, Tong and Koczywas, Marianna and Gandara, David R and Newman, Edward M
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 10/2018, Volume 82, Issue 4, pp. 723 - 732
Tyrosine kinase inhibitors (TKI) that target MET signaling have shown promise in various types of cancer, including lung cancer. Combination strategies have... 
Medicine & Public Health | MET phosphorylation | Oncology | Cancer Research | Topotecan | Circulating tumor cells | Pharmacology/Toxicology | Tivantinib | ARQ-197 | ADULT PATIENTS | ARQ 197 MONOTHERAPY | COMBINATION | CELL LUNG-CANCER | DOSE-ESCALATION | HEPATOCELLULAR-CARCINOMA | INHIBITION | THERAPY | ONCOLOGY | C-MET | GROWTH | PHARMACOLOGY & PHARMACY | Antimitotic agents | Care and treatment | Lung cancer | Analysis | Clinical trials | Product development | Antineoplastic agents | Cancer | Tyrosine | Thrombocytopenia | Phosphorylation | Toxicity | Tumor cells | DNA topoisomerase | Pharmacology | Patients | c-Met protein | Granulocyte colony-stimulating factor | Solid tumors | Protein-tyrosine kinase | Tumors | Neutropenia | circulating tumor cells | topotecan
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Abstract A1-36: The genomics of young lung cancer
by Gitlitz, Barbara J and Morosini, Deborah and Sable-Hunt, Alicia and Addario, Bonnie J and Oxnard, Geoffrey R
Cancer Research, ISSN 0008-5472, 11/2015, Volume 75, Issue 22 Supplement 1, pp. A1 - A1-36
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text The genomics of Young Lung Cancer Study
by Gitlitz, Barbara J and Morosini, Deborah and Sable-Hunt, Alicia L and Addario, Bonnie J and Jennings, Mark Byron and Mach, Stacy L and Oxnard, Geoffrey R
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. TPS11110 - TPS11110
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Phase II trial of cabozantinib plus erlotinib in patients with advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer with progressive disease on epidermal growth factor receptor tyrosine kinase inhibitor therapy: A California cancer consortium phase II trial (NCI 9303)
by Reckamp, Karen L and Frankel, Paul H and Ruel, Nora and Mack, Philip C and Gitlitz, Barbara J and Li, Tianhong and Koczywas, Marianna and Gadgeel, Shirish M and Cristea, Mihaela C and Belani, Chandra P and Newman, Edward M and Gandara, David R and Lara, Primo N
Frontiers in Oncology, ISSN 2234-943X, 2019, Volume 9, p. 132
Introduction: Mesenchymal epidermal transition and vascular endothelial growth factor pathways are important in mediating non-small cell lung cancer (NSCLC)... 
RET | TKI resistance | MET | VEGF | EGFR | Non-small cell lung cancer | non-small cell lung cancer | GEFITINIB | MULTICENTER | XL184 | ACQUIRED-RESISTANCE | OPEN-LABEL | EGFR MUTATIONS | MET AMPLIFICATION | ONCOLOGY | Erlotinib | Gene mutations | Development and progression | Dosage and administration | Genetic aspects | Research | Lung cancer, Non-small cell | Drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text A randomized phase II trial of the MET inhibitor tivantinib + cetuximab versus cetuximab alone in patients with recurrent/metastatic head and neck cancer
by Vokes, Everett E and Worden, Francis P and Adkins, Douglas and Bauman, Julie E and Lim, Dean and Sukari, Ammar and Rao, Krishna A and Wagner, Stephanie Ann and Curtis, Kelly Kevelin and Gitlitz, Barbara J and Price, Katharine Andress Rowe and Wade, James Lloyd and Villaflor, Victoria Meucci and De Souza, Jonas A and Karrison, Theodore and Stadler, Walter Michael and Seiwert, Tanguy Y
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. 6060 - 6060
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Ensartinib (X-396) in ALK-positive non–small cell lung cancer: Results from a first-in-human phase I/II, multicenter study
by Horn, Leora and Infante, Jeffrey R and Reckamp, Karen L and Blumenschein, George R and Leal, Ticiana A and Waqar, Saiama N and Gitlitz, Barbara J and Sanborn, Rachel E and Whisenant, Jennifer G and Du, Liping and Neal, Joel W and Gockerman, Jon P and Dukart, Gary and Harrow, Kimberly and Liang, Chris and Gibbons, James J and Holzhausen, Allison and Lovly, Christine M and Wakelee, Heather A
Clinical Cancer Research, ISSN 1078-0432, 06/2018, Volume 24, Issue 12, pp. 2771 - 2779
Purpose: Evaluate: safety and determine the recommended phase II dose (RI , 21)) of ensartinib (X-396), a potent anaplastic lymphoma kinase (ALK) tyrosine... 
ANAPLASTIC LYMPHOMA KINASE | ONCOLOGY | CERITINIB | EML4-ALK FUSION GENE | CRIZOTINIB | OPEN-LABEL | SINGLE-ARM | INHIBITOR | IDENTIFICATION | CHEMOTHERAPY | Tyrosine | Brain | Toxicity | Exanthema | Lung cancer | Brain tumors | Central nervous system | Non-small cell lung carcinoma | Fatigue | Nausea | Pharmacology | Pruritus | Patients | Lymphoma | Metastases | Anticancer properties | Vomiting | Antitumor activity | Solid tumors | Pharmacokinetics | Protein-tyrosine kinase | Cancer | Index Medicus | non-small cell lung cancer | ALK inhibitor | ensartinib | X-396 | first-in-human study
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Eribulin: a new-generation antimicrotubule agent in lung cancer therapy
by Thara, Eddie and Gitlitz, Barbara J
Future oncology (London, England), 10/2014, Volume 10, Issue 12, p. 1913
Microtubule antagonists are highly active agents for treatment of metastatic lung cancer, but can lead to significant toxicities and tumor resistance. Eribulin... 
Ketones - pharmacology | Lung Neoplasms - drug therapy | Animals | Tubulin Modulators - pharmacology | Furans - pharmacology | Humans | Antineoplastic Agents - pharmacology
Journal Article
Details down arrow
8. Full Text Changes in 18 F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib
by Mileshkin, Linda and Hicks, Rodney J and Hughes, Brett G. M and Mitchell, Paul L. R and Charu, Veena and Gitlitz, Barbara J and Macfarlane, David and Solomon, Benjamin and Amler, Lukas C and Yu, Wei and Pirzkall, Andrea and Fine, Bernard M
Clinical Cancer Research, ISSN 1078-0432, 05/2011, Volume 17, Issue 10, pp. 3304 - 3315
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: An international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742)
by Ma, Brigette B.Y and Lim, Wan-Teck and Goh, Boon-Cher and Hui, Edwin P and Lo, Kwok-Wai and Pettinger, Adam and Foster, Nathan R and Riess, Jonathan W and Agulnik, Mark and Chang, Alex Y.C and Chopra, Akhil and Kish, Julie A and Chung, Christine H and Adkins, Douglas R and Cullen, Kevin J and Gitlitz, Barbara J and Lim, Dean W and To, Ka-Fai and Chan, K.C. Allen and Lo, Y.M. Dennis and King, Ann D and Erlichman, Charles and Yin, Jun and Costello, Brian A and Chan, Anthony T.C
Journal of Clinical Oncology, ISSN 0732-183X, 2018, Volume 36, Issue 14, pp. 1412 - 1418
PurposeThis multinational study evaluated the antitumor activity of nivolumab in nasopharyngeal carcinoma (NPC). Tumor and plasma-based biomarkers were... 
THERAPY | MELANOMA | BARR-VIRUS DNA | ONCOLOGY | PD-L1 EXPRESSION | MUTATIONS | BLOCKADE | CANCER | SUBSET | CELL CARCINOMA | ESCAPE | ORIGINAL REPORTS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Improved Prognostication of Renal Cell Carcinoma Using an Integrated Staging System
by Amnon Zisman and Allan J. Pantuck and Fredrick Dorey and Jonathan W. Said and Oleg Shvarts and Deanna Quintana and Barbara J. Gitlitz and Jean B. deKernion and Robert A. Figlin and Arie S. Belldegrun
Journal of Clinical Oncology, ISSN 0732-183X, 03/2001, Volume 19, Issue 6, pp. 1649 - 1657
Purpose: To integrate stage, grade, and Eastern Cooperative Oncology Group (ECOG) performance status (PS) into a clinically useful fool capable of stratifying... 
SURVIVAL | GRADE | ONCOLOGY | PROGNOSIS | MORPHOLOGIC PARAMETERS | Prognosis | Carcinoma, Renal Cell - pathology | Humans | Middle Aged | Kidney Neoplasms - classification | Carcinoma, Renal Cell - classification | Male | Neoplasm Staging - methods | Endpoint Determination | Survival Analysis | Aged, 80 and over | Adult | Female | Kidney Neoplasms - pathology | Aged | Retrospective Studies | Health Status
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text EGFR fusions as novel therapeutic targets in lung cancer
by Konduri, Kartik and Gallant, Jean-Nicolas and Chae, Young Kwang and Giles, Francis J and Gitlitz, Barbara J and Gowen, Kyle and Ichihara, Eiki and Owonikoko, Taofeek K and Peddareddigari, Vijay and Ramalingam, Suresh S and Reddy, Satyanarayan K and Eaby-Sandy, Beth and Vavalà, Tiziana and Whiteley, Andrew and Chen, Heidi and Yan, Yingjun and Sheehan, Jonathan H and Meiler, Jens and Morosini, Deborah and Ross, Jeffrey S and Stephens, Philip J and Miller, Vincent A and Ali, Siraj M and Lovly, Christine M
Cancer Discovery, ISSN 2159-8274, 06/2016, Volume 6, Issue 6, pp. 601 - 611
Here, we report that novel epidermal growth factor receptor (EGFR) gene fusions comprising the N-terminal of EGFR linked to various fusion partners, most... 
CETUXIMAB | GEFITINIB | GENE | ONCOLOGY | ADENOCARCINOMA | EPIDERMAL-GROWTH-FACTOR | PHASE-III | OPEN-LABEL | MUTATIONS | FACTOR RECEPTOR | KINASE DOMAIN | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Exons | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Genetic Loci | Molecular Targeted Therapy | Young Adult | Neoplasm Metastasis | Oncogene Proteins, Fusion - chemistry | Adult | Female | Antineoplastic Agents - pharmacology | Lung Neoplasms - genetics | Rad51 Recombinase - genetics | Introns | Models, Molecular | Combined Modality Therapy | Magnetic Resonance Imaging | Oncogene Proteins, Fusion - genetics | Protein Kinase Inhibitors - therapeutic use | Biomarkers | Cell Line, Tumor | Oncogene Proteins, Fusion - antagonists & inhibitors | Protein Conformation | High-Throughput Nucleotide Sequencing | Protein Kinase Inhibitors - pharmacology | Lung Neoplasms - diagnosis | targeted therapy | afatinib | Epidermal growth factor receptor (EGFR) | next-generation sequencing (NGS) | erlotinib | osimertinib | kinase domain | cetuximab | gene rearrangement | kinase fusion | tyrosine kinase inhibitor (TKI) | non-small cell lung cancer (NSCLC)
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib
by Ou, Sai-Hong Ignatius and Schrock, Alexa B and Bocharov, Eduard V and Klempner, Samuel J and Haddad, Carolina Kawamura and Steinecker, Gary and Johnson, Melissa and Gitlitz, Barbara J and Chung, Jon and Campregher, Paulo V and Ross, Jeffrey S and Stephens, Philip J and Miller, Vincent A and Suh, James H and Ali, Siraj M and Velcheti, Vamsidhar
Journal of Thoracic Oncology, ISSN 1556-0864, 03/2017, Volume 12, Issue 3, pp. 446 - 457
Erb-b2 receptor tyrosine kinase (HER2) transmembrane domain (TMD) mutations (HER2 , HER2 ) have previously been identified in lung adenocarcinomas, but their... 
HER2 G660 | Actionable driver mutation | HER2 V659 | NSCLC | Afatinib | Transmembrane mutation | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Protein Multimerization | Receptor, ErbB-2 - chemistry | Lung Neoplasms - pathology | Male | Radiation-Sensitizing Agents - therapeutic use | Protein Domains | Adult | Female | Retrospective Studies | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Amino Acid Sequence | Carcinoma, Non-Small-Cell Lung - genetics | Sequence Alignment | Quinazolines - therapeutic use | Protein Conformation | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Eribulin: A new-generation antimicrotubule agent in lung cancer therapy
by Thara, Eddie and Gitlitz, Barbara J
Future Oncology, ISSN 1479-6694, 10/2014, Volume 10, Issue 12, pp. 1913 - 1924
Microtubule antagonists are highly active agents for treatment of metastatic lung cancer, but can lead to significant toxicities and tumor resistance. Eribulin... 
lung cancer | antimicrotubule | halichondrin | eribulin | taxanes | HALICHONDRIN-B | MECHANISM | MESYLATE E7389 | NATURAL-PRODUCTS | PHASE-II | ONCOLOGY | DYNAMICS | TUBULIN | CELL | BINDING
Journal Article
Details down arrow
14. Full Text Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs
by Vannini, Ivan and Wise, Petra M and Challagundla, Kishore B and Plousiou, Meropi and Raffini, Mirco and Bandini, Erika and Fanini, Francesca and Paliaga, Giorgia and Crawford, Melissa and Ferracin, Manuela and Ivan, Cristina and Fabris, Linda and Davuluri, Ramana V and Guo, Zhiyi and Cortez, Maria Angelica and Zhang, Xinna and Chen, Lu and Zhang, Shuxing and Fernandez-Cymering, Cecilia and Han, Leng and Carloni, Silvia and Salvi, Samanta and Ling, Hui and Murtadha, Mariam and Neviani, Paolo and Gitlitz, Barbara J and Laird-Offringa, Ite A and Nana-Sinkam, Patrick and Negrini, Massimo and Liang, Han and Amadori, Dino and Cimmino, Amelia and Fabbri, Muller and Calin, George A
Nature Communications, ISSN 2041-1723, 12/2017, Volume 8, Issue 1, pp. 1801 - 19
The transcribed ultraconserved regions (T-UCRs) encode long non-coding RNAs implicated in human carcinogenesis. Their mechanisms of action and the factors... 
MYC MESSENGER-RNA | LUNG-CANCER | CYCLIN-E | LONG NONCODING RNA | MULTIDISCIPLINARY SCIENCES | C-MYC | CELL-PROLIFERATION | CERNA HYPOTHESIS | EXPRESSION | P53 | Carcinogens | Cell survival | p53 Protein | Lung cancer | MicroRNAs | MiRNA | Cell lines | Non-small cell lung carcinoma | Tumor suppressor genes | Ribonucleic acid--RNA | Carcinogenesis | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?
by Ou, Sai-Hong Ignatius and Lee, Thomas K and Young, Lauren and Fernandez-Rocha, Maria Y and Pavlick, Dean and Schrock, Alexa B and Zhu, Viola W and Milliken, Jeffrey and Ali, Siraj M and Gitlitz, Barbara J
Lung Cancer, ISSN 0169-5002, 2017, Volume 106, pp. 110 - 114
Highlights • SCLC transformation is a resistance mechanism to ALK inhibitors. • Liquid biopsy missed morphologic examination. • Emergence of Rb1 C706Y and p53... 
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | Small cell lung cancer transformation | ALK G1202R solvent front mutation | Lorlatinib | Rb1 C706Y | Circulating tumor DNA | ALK+ NSCLC | ADENOCARCINOMA | EML4-ALK FUSION | ACQUIRED-RESISTANCE | 1ST | ALK plus NSCLC | ONCOLOGY | RESPIRATORY SYSTEM | ALECTINIB | Rbl C706Y | Lung Neoplasms - drug therapy | Humans | Lung Neoplasms - metabolism | Middle Aged | Lung Neoplasms - pathology | Male | Small Cell Lung Carcinoma - drug therapy | Small Cell Lung Carcinoma - metabolism | Cell Transformation, Neoplastic - genetics | Fatal Outcome | Adult | Female | Lactams, Macrocyclic - administration & dosage | Lactams, Macrocyclic - therapeutic use | Retinoblastoma Binding Proteins - genetics | Carcinoma, Non-Small-Cell Lung - pathology | Pyridines | Neoplastic Cells, Circulating - drug effects | Liquid Biopsy - methods | Pyrazoles | Carcinoma, Non-Small-Cell Lung - metabolism | Disease Progression | Drug Resistance, Neoplasm - genetics | Small Cell Lung Carcinoma - pathology | Receptor Protein-Tyrosine Kinases - genetics | Protein Kinase Inhibitors - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Ubiquitin-Protein Ligases - genetics | Tumor proteins | Medical colleges | Genetic aspects | Development and progression | Lung cancer, Small cell | Lung cancer, Non-small cell
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text The genomics of young lung cancer
by Gitlitz, Barbara J and Morosini, Deborah and Sable-Hunt, Alicia L and Addario, Bonnie J and Mach, Stacy L and Jennings, Mark Byron and Park, S. Lani and Bittoni, Marisa A and Oxnard, Geoffrey R
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. 9083 - 9083
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Publisher Correction: Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs (Nature Communications DOI: 10.1038/s41467-017-01562-9)
by Vannini, Ivan and Wise, Petra M and Challagundla, Kishore B and Plousiou, Meropi and Raffini, Mirco and Bandini, Erika and Fanini, Francesca and Paliaga, Giorgia and Crawford, Melissa and Ferracin, Manuela and Ivan, Cristina and Fabris, Linda and Davuluri, Ramana V and Guo, Zhiyi and Cortez, Maria Angelica and Zhang, Xinna and Chen, Lu and Zhang, Shuxing and Fernandez-Cymering, Cecilia and Han, Leng and Carloni, Silvia and Salvi, Samanta and Ling, Hui and Murtadha, Mariam and Neviani, Paolo and Gitlitz, Barbara J and Laird-Offringa, Ite A and Nana-Sinkam, Patrick and Negrini, Massimo and Liang, Han and Amadori, Dino and Cimmino, Amelia and Calin, George A and Fabbri, Muller
Nature Communications, ISSN 2041-1723, 12/2018, Volume 9, Issue 1, pp. 160 - 160
In the originally published version of this Article, the positions of the final two authors in the author list were inadvertently inverted during the... 
Tumor suppressor genes | Carcinogens | Error correction | Carcinogenesis | MiRNA
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Phase I study of bosutinib, a Src/Abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors
by Daud, Adil I and Krishnamurthi, Smitha S and Saleh, Mansoor N and Gitlitz, Barbara J and Borad, Mitesh J and Gold, Philip J and Chiorean, Elena G and Springett, Gregory M and Abbas, Richat and Agarwal, Shefali and Bardy-Bouxin, Nathalie and Hsyu, Poe-Hirr and Leip, Eric and Turnbull, Kathleen and Zacharchuk, Charles and Messersmith, Wells A
Clinical Cancer Research, ISSN 1078-0432, 02/2012, Volume 18, Issue 4, pp. 1092 - 1100
Purpose: Bosutinib, a potent ATP-competitive, quinolinecarbonitrile Src/Abl kinase inhibitor, was tested in this first-in-human phase I trial in patients with... 
SRC INHIBITORS | ACTIVATION | INVASION | AZD0530 | EFFICACY | ONCOLOGY | PROSTATE-CANCER | THERAPEUTIC AGENTS | DASATINIB | SKI-606 BOSUTINIB | IDENTIFICATION | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Quinolines - administration & dosage | Nitriles - administration & dosage | Young Adult | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Aniline Compounds - administration & dosage | Neoplasms - mortality | Treatment Outcome | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Survival Analysis | Aged | Quinolines - therapeutic use | Aniline Compounds - therapeutic use | Aniline Compounds - adverse effects | Neoplasm Staging | Neoplasms - pathology | Nitriles - adverse effects | Quinolines - adverse effects | Nitriles - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text Renal Cell Carcinoma With Retroperitoneal Lymph Nodes: Role of Lymph Node Dissection
by PANTUCK, ALLAN J and ZISMAN, AMNON and DOREY, FREDRICK and CHAO, DEBBY H and HAN, KEN-ryu and SAID, JONATHAN and GITLITZ, BARBARA J and FIGLIN, ROBERT A and BELLDEGRUN, ARIE S
The Journal of Urology, ISSN 0022-5347, 2003, Volume 169, Issue 6, pp. 2076 - 2083
We better defined the benefits and morbidity of lymph node dissection in patients with localized renal cell carcinoma using the experience of patients treated... 
kidney | lymph node dissection | carcinoma, renal cell | survival | immunotherapy | Lymph node dissection | Carcinoma, renal cell | Survival | Immunotherapy | Kidney | SURGERY | CLASSIFICATION | NATURAL-HISTORY | CANCER | RADICAL NEPHRECTOMY | LYMPHADENECTOMY | GROWTH | UROLOGY & NEPHROLOGY | SPREAD | EXPRESSION | Lymph Node Excision | Recombinant Proteins - therapeutic use | Outcome Assessment (Health Care) | Carcinoma, Renal Cell - pathology | Humans | Interleukin-2 - therapeutic use | Carcinoma, Renal Cell - surgery | Male | Survival Rate | Combined Modality Therapy | Lymphatic Metastasis | Kidney Neoplasms - mortality | Carcinoma, Renal Cell - mortality | Kidney Neoplasms - surgery | Regression Analysis | Analysis of Variance | Nephrectomy | Retroperitoneal Space | Carcinoma, Renal Cell - secondary | Female | Kidney Neoplasms - pathology | Retrospective Studies | Surgery | Carcinoma, Renal cell
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text Epigenetic therapy in lung cancer
by Liu, Stephen V and Fabbri, Muller and Gitlitz, Barbara J and Laird-Offringa, Ite A
Frontiers in Oncology, ISSN 2234-943X, 2013, Volume 3, p. 135
Epigenetic deregulation of gene function has been strongly implicated in carcinogenesis and is one of the mechanisms contributing to the development of lung... 
DNA methylation | Epigenetics | Histone deacetylase inhibitors | Lung cancer | MicroRNAs | Hypomethylating agent | lung cancer | DNA Methylation | Histone deacetylase inhibitor | Hypomethylating Agent | epigenetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.